A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Eikon Therapeutics
Study ID
NCT06253130
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • IMP1734 — DRUG
    PARP1 selective inhibitor

Study Details

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Key Dates

Start date
Dec 11, 2023
Status verified
Mar 2026
Primary completion
Jun 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
156 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial.

Primary Outcome Measure

Number of subjects with adverse events, treatment emergent adverse events or serious adverse events [ Time Frame: Consent to 30 + 7 days post last dose of IMP1734 ]

Central Contacts

Locations (23)

FacilityCityStateZIPSite coordinators
The University of Arizona Cancer CenterTucsonArizona85719
Spencer Study Coordinator
[email protected]
520-694-4374
Alejandro Recio-Boiles, MD (PRINCIPAL_INVESTIGATOR)
University of Arkansas Winthrop P. Rockefeller Cancer InstituteLittle RockArkansas72205
Maroof Study Coordinator
[email protected]
501-686-8274
Michael Birrer, MD (PRINCIPAL_INVESTIGATOR)
Hoag Health Center IrvineIrvineCalifornia92618
Ariel Study Coordinator
[email protected]
949-764-6755
Monica Mita, MD (PRINCIPAL_INVESTIGATOR)
University California IrvineIrvineCalifornia92868-
Sharp Memorial HospitalSan DiegoCalifornia92123-
University of California San Francisco (UCSF)San FranciscoCalifornia94158-
Sarah Cannon Research Institute Health OneDenverColorado80218
Hannah Study Nurse
[email protected]
720-754-2610
Gerald Falchook, MD (PRINCIPAL_INVESTIGATOR)
Smilow Cancer Hospital at Yale New HavenNew HavenConnecticut06511
Sarah Reinwald
[email protected]
203-314-7175
Patricia LoRusso, MD (PRINCIPAL_INVESTIGATOR)
Advent Health Research InstituteCelebrationFlorida34747
Jamayra Study Coordinator
[email protected]
Guru Sonpavde, MD (PRINCIPAL_INVESTIGATOR)
Sylvester Comprehensive Cancer CenterMiamiFlorida33136
Lauren Study Coordinator
[email protected]
305-243-8237
Frances Valdes-Albini, MD (PRINCIPAL_INVESTIGATOR)
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109
Myron Study Coordinator
[email protected]
734-998-4415
Aki Morikawa, MD (PRINCIPAL_INVESTIGATOR)
Henry Ford HealthDetroitMichigan48202
Andrew Study Coordinator
[email protected]
313-439-0182
Amy Weise, MD (PRINCIPAL_INVESTIGATOR)
Karmanos Cancer InstituteDetroitMichigan48201
Brenda Research Nurse
[email protected]
313-576-8408
Yusra Shao, MD (PRINCIPAL_INVESTIGATOR)
University of Minnesota-Clinical Research UnitMinneapolisMinnesota55455
Elizabeth Study Coordinator
[email protected]
612-626-1358
Heather Beckwith, MD (PRINCIPAL_INVESTIGATOR)
Washington University - Siteman Cancer CenterSt LouisMissouri63110-
John Theurer Cancer CenterHackensackNew Jersey07601-
Cayuga Medical CenterIthacaNew York14850-
Lifespan Cancer InstituteProvidenceRhode Island02903
Sopha Research Nurse
[email protected]
401.444.8946
Benedito Carneiro, MD (PRINCIPAL_INVESTIGATOR)
Medical University of South Carolina (MUSC) - Hollings CCCharlestonSouth Carolina29425
Abigail Study Coordinator
[email protected]
Brian Orr, MD (PRINCIPAL_INVESTIGATOR)
West Cancer Center & Research InstituteGermantownTennessee38138
Rebecca Study Coordinator
[email protected]
Daniel Vaena, MD (PRINCIPAL_INVESTIGATOR)
Sarah Cannon Research Institue OncologyNashvilleTennessee37203
Emma Study Coordinator
[email protected]
(615) 917 - 9153
Benjamin Garmezy, MD (PRINCIPAL_INVESTIGATOR)
START - South Texas Accelerated Research TherapeuticsSan AntonioTexas78229-
START Mountain RegionWest Valley CityUtah84119-

Find similar trials in Tucson, AZ

By research site
The University of Arizona Cancer Center· Tucson, AZUniversity of Arkansas Winthrop P. Rockefeller Cancer Institute· Little Rock, ARHoag Health Center Irvine· Irvine, CAUniversity California Irvine· Irvine, CASharp Memorial Hospital· San Diego, CAUniversity of California San Francisco (UCSF)· San Francisco, CA

Related Studies